Fitbit CEO James Park reminded investors that his product is very different from the Apple watch.
"We are a fitness social network that is coupled to hardware, and we are on the cusp of transitioning the mission and purpose of our company from a consumer electronics company to a digital healthcare company," Park said.
Fitbit's focus is very different from Apple, Park said. The company aims to encourage users to become healthier and more active, whether it is through the use of its devices, software or services. Park said the social aspect of the product drives Fitbit's growth.
The rising growth of health-conscious people has also made them more curious about genetic diseases. 23andMe is a privately-held company that provides DNA accessible testing to the masses.
The company first started out as a way for users to learn more about their ancestry, allowing them to provide DNA samples through the mail. 23andMe also utilizes the data to assist with medical research, help research organizations with drug discovery and have further clarification on the role of genetics.
Cramer spoke with 23andMe's CEO Anne Wojcicki, who said she has learned that consumers want to have more control and power over their health.
"23andMe is leading the charge of this whole movement of the consumer actually paying it for themselves, making it affordable, and actually owning the information and taking responsibility for what they learn and implementing that into their daily lives," Wojcicki said.
In the Lightning Round, Cramer gave his take on a few caller favorite stocks:
AMN Healthcare Services: "I talk to Susan Salka [CEO] pretty regularly. I don't think anything is wrong with the stock. I think it's terrific at hospital staffing. Medical staffing is the place to be, I would be a buyer of what Susan Salka is doing."
MiMedx Group: "It is on my list for companies to look at. I am not there yet. You know I like the medical device companies. Let me do more work and come back."
Correction: This article was updated to reflect that 23andMe has assisted in medical research for more than one year, and does not provide a report on an individual's predisposition to conditions.